36 results about "B hepatitis surface" patented technology

The present invention relates to an eudesmane type sesquiterpene derivative 1 beta-hydroxyilicic acid, namely 1 beta-hydroxy-5 alpha H-eudesmane-11 (13)-ethylene-12-acid, its medicineal salt or solvent compound and its medicine composition and medicinal application for preparing medicine capable of curing hepatitis B virus infective disease and resisting hepatitis B virus. Said invention also provides its chemical structure formula.

Reagents, methods and immunodiagnostic test kits for the accurate detection of hepatitis B virus (HBV) infection are disclosed. The methods and kits employ novel rabbit monoclonal antibodies directed against HBV surface antigens (HBsAg) with mutations in the “a” determinant region of HBsAg.

The invention discloses a lucid ganoderma-Cordyceps sinensis granule. A preparation method for the granule comprises the following steps: subjecting purely natural lucid ganoderma to reflux extraction with 70 to 90% ethanol, carrying out pressure reduced condensation, settlement with a ZTC clarifying agent and combination of extracts obtained after extraction three times, filtering the combined extract, then carrying out standing for 10 to 25 h and centrifugation, collecting a precipitate, adding distilled water to dissolve the precipitate, boiling the dissolved precipitate, filtering out insoluble substances while the dissolved precipitate is hot, adding ethanol into an obtained filtrate with stirring until alcohol content reaches 80%, carrying out standing to allow a grayish purple precipitate to be precipitated, drying the grayish purple precipitate at a low temperature to obtain a crude lucid ganoderma polysaccharide product, subjecting the crude lucid ganoderma polysaccharide product to repeated washing and precipitation with 50 to 80% ethanol, carrying out continuous elution and dissolution by using distilled water, concentrating an eluate, adding ethanol until alcohol content reaches 70%, carrying out standing to allow a precipitate to be filtered and drying the precipitate at a low temperature so as to obtain lucid ganoderma polysaccharide; and processing a lucid ganoderma extract particle from 50 to 80% of the lucid ganoderma polysaccharide and mixing the particle and Cordyceps sinensis mycelia according to a ratio of 1: 9 so as to prepare the lucid ganoderma-Cordyceps sinensis granule. The lucid ganoderma-Cordyceps sinensis granule provided by the invention has an immunoloregulation function, enables negative conversion of a hepatitis B surface antigen to be realized and has energy invigorating, foundation strengthening, liver and kidney nourishing, blood circulation promoting and blood stasis removing effects.

The invention discloses a method for constructing eukaryon Hansenula polymorpha with recombinant hepatitis B virus genes and a method for producing hepatitis B surface antigens, and belongs to the technical field of bioengineering. The method for constructing the eukaryon Hansenula polymorpha includes steps of 1, constructing plasmids pHPZF1.0-ZS with the recombinant hepatitis B virus HBsAg genes; 2, screening the plasmids to obtain the eukaryon Hansenula polymorpha engineering bacteria with the recombinant hepatitis virus HBsAg genes and the highest expression level. The methods have the advantages that HBsAg recombinant proteins can be stably and efficiently expressed in a methanol induction mode by Hansenula polymorpha engineering bacterial strains of the hepatitis B surface antigens which can be obtained by the aid of the methods, and the methods are suitable for producing the HBsAg recombinant proteins on a large scale.

An immunogenic composition comprising of Diphtheria toxoid antigen (D), tetanus toxoid (T) antigen, Hepatitis B surface antigen (HBsAg), inactivated whole-cell B. pertussis (wP) antigen, Haemophilus influenzae type B (Hib) capsular saccharide conjugated to a carrier protein, Inactivated Polio Virus (IPV) antigen and additionally one or more antigens and the method of preparing the same. A fully liquid combination vaccine, showing improved immunogenicity, reduced reactogenicity and improved stability. Improved methods of formaldehyde inactivation, improved adsorption profile of Diphtheria toxoid antigen (D), tetanus toxoid (T) antigen and Hepatitis B (HepB) surface antigen adsorbed individually onto aluminium phosphate adjuvant, minimum total aluminum content (Al³⁺) and optimized concentration of 2-phenoxyethanol (2-PE) as preservative.

An object of the present invention is to provide a compound or a salt thereof having anti-HBV activity, a pharmaceutical composition, an anti-hepatitis B virus agent, a production inhibitor of DNA of a hepatitis B virus, and a production or secretion inhibitor of a hepatitis B surface antigen. According to the present invention, provided are a compound represented by General Formula [1] or a salt thereof:

The invention provides an antibody (in particular, a humanized antibody) against hepatitis B surface antigen (HBsAg), a nucleic acid molecule encoding the same, a method for preparing the same, and a pharmaceutical composition comprising the same. The invention also provides use of the antibody and pharmaceutical composition. The antibody and pharmaceutical composition according to the invention can be used for preventing and/or treating HBV infection or a disease associated with HBV infection (such as Hepatitis B), for neutralizing HBV virulence in a subject (such as human), or for reducing the serum level of HBV DNA and/or HBsAg in a subject.

The invention provides a hepatitis B virus adsorbent based on a nanostructure as well as a preparation method and an application of the hepatitis B virus adsorbent. The method comprises the following steps: synthesizing a DNA nano-material with a specific structure, and connecting the DNA nano-material with an aptamer to obtain a DNA nano-material connected with the aptamer; and loading the DNA nano material connected with the aptamer on a specific adsorption carrier to obtain the hepatitis B virus adsorbent based on the nano structure. Through the mode, the DNA nano material can be used as an intermediate structure for connecting the aptamer and the adsorption carrier, so that complex operation required when the aptamer and the adsorption carrier are directly coupled can be avoided, and the preparation process is simplified; meanwhile, the adsorption efficiency of the adsorbent can be effectively improved while the aptamer and the adsorption carrier are stably connected, so that efficient adsorption of the hepatitis B surface antigen is realized, the content of the hepatitis B surface antigen in blood is greatly reduced, and the adsorbent has a relatively high practical application value.

The invention provides a hepatitis B virus adsorbent as well as a preparation method and application thereof. The preparation method comprises the following steps: mixing Nhydroxysuccinimide and 1 (3-dimethylaminopropyl) 3ethylcarbodiimide hydrochloride, and dissolving the mixture in a buffer solution to prepare a cross-linking catalyst; adding the obtained cross-linking catalyst into a carboxylated agarose gel microsphere suspension, fully and uniformly mixing, then adding a dissolved amino-modified nucleic acid aptamer, and directly coupling the carboxylated agarose gel microsphere with the amino-modified nucleic acid aptamer by virtue of amidation reaction, and therefore, the hepatitis B virus adsorbent is simply, conveniently and efficiently prepared. By means of the mode, the nucleic acid aptamer can replace a traditional antibody to serve as a ligand, the prepared adsorbent has higher adsorption efficiency, effective adsorption of the hepatitis B surface antigen is achieved, and therefore the content of the hepatitis B surface antigen in blood is effectively reduced, and high practical application value is achieved.

The invention provides a hepatitis B surface antigen detection method, which comprises the following steps: (1) preparing a serum sample, namely, collecting venous blood, separating the venous blood to obtain serum, and carrying out high-speed centrifugation on the serum 1-2 times to obtain a serum sample to be detected, wherein the high-speed centrifugal conditions are as follows: the temperatureis 4-10 DEG C, the speed is 10000-15000rpm/min, and the time is 3-8min; (2) adding a sample, namely, adding 40-50 [mu] L of the serum sample to be detected into a reaction hole coated with a monoclonal antibody aiming at the hepatitis B surface antigen, wherein the clone number of the monoclonal antibody is 86C; (3) adding an enzyme-labeled antibody, namely, adding 50+/-1 [mu] L of the enzyme-labeled antibody into the reaction hole, then covering a reaction plate with a plate sealing film, and incubating the reaction plate at 37+/-1 DEG C for 35-45min; (4) washing; (5) developing; (6) terminating; (7) measuring. The detection method can realize accurate detection of the hepatitis B surface antigen, and particularly has the advantages of smaller sample size required, clear and clean reaction hole body and low background when being used for detecting people with hyperlipidemia.

A pharmaceutical composition for use in treating hepatitis B virus (HBV) infection includes an effective amount of an antibody against CD11b or a binding fragment thereof. A method for treating hepatitis B virus infection includes administering to a subject in need thereof an antibody against CD11b. Anti-CD11b antibody binding to CD11b may trigger immunostimulatory responses, as evidenced by the following observations: increased surface expression of MHC II and CD86 in CD11b+ peripheral blood mononuclear cells (PBMCs); suppressed level of hepatitis B surface antigen (HBsAg) and HBV DNA in the blood; and accelerated clearance of HBV from liver.

Disclosed are antibodies to anti-hepatitis B surface antigen (HBsAg) (especially humanized antibodies), nucleic acid molecules encoding same, methods for preparing same, and pharmaceutical compositions containing same. The antibodies have higher affinity for HBsAg at neutral pH than at acidic pH, thereby significantly enhancing the virus clearance efficiency and prolonging the virus inhibition time. The antibodies and the pharmaceutical compositions can be used for preventing and/or treating HBV infections or diseases related to HBV infections (e.g., hepatitis B), for neutralizing the virulence of HBV in a subject (e.g., a human), for reducing the serum level of HBV DNA and/or HBsAg in the body of the subject, or for activating the humoral immune response of the subject (e.g., a chronic HBV infected or chronic hepatitis B patient) against HBV.

There is provided a method of treating chronic hepatitis B infection (CHB) in a human, comprising the steps of:

• • a) administering to the human a composition comprising a replication-defective chimpanzee adenoviral (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc);
  • b) administering to the human a composition comprising a Modified Vaccinia Virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); and
  • c) administering to the human a composition comprising a recombinant hepatitis B surface antigen (HBs), recombinant hepatitis B virus core antigen (HBc) and an adjuvant.

The invention discloses a test strip for detecting hepatitis B surface antigen and a preparation method thereof, and the preparation method comprises the following steps: S1, preparing a sample pad treating fluid, and treating a glass fiber membrane through the sample pad treating fluid to prepare a sample pad; s2, preparing a gold-labeled pad treating fluid, and treating the glass fiber membrane through the gold-labeled pad treating fluid to obtain a gold-labeled pad; and S3, preparing monoclonal antibody immune gold for resisting the hepatitis B virus surface antigen, and spraying the prepared immune gold on the treated gold label pad according to 3 [mu] l/cm by using a gold spraying and membrane scratching all-in-one machine. Based on the immune lateral flow chromatography technology, instruments are not needed in the detection process, and whether the hepatitis B surface antigen exists in blood or not can be judged through naked eyes; the detection result is accurate, the detection time is short, and the body of a detected person cannot be injured; because the detection time is short, acute detection can be carried out on a patient before an operation, so that the protection of medical personnel is facilitated, and the transmission of infectious diseases is effectively blocked.